These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22359923)

  • 21. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
    Shmidt TE; Zhuchenko TD; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].
    Sazonov DV; Malkova NA; Bulatova EV; Riabukhina OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12):76-9. PubMed ID: 20037526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
    Gironi M; Borgiani B; Mariani E; Cursano C; Mendozzi L; Cavarretta R; Saresella M; Clerici M; Comi G; Rovaris M; Furlan R
    J Immunol Res; 2014; 2014():961863. PubMed ID: 24741637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Chitosan on the Erythrocyte Antioxidant Potential of Lead Toxicity-Induced Rats.
    Toz H; Değer Y
    Biol Trace Elem Res; 2018 Jul; 184(1):114-118. PubMed ID: 28971372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why treat early multiple sclerosis patients?
    Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):235-40. PubMed ID: 10871245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
    Yong VW
    Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of subacute treatment of some plant growth regulators on serum marker enzymes and erythrocyte and tissue antioxidant defense and lipid peroxidation in rats.
    Celik I; Tuluce Y; Isik I
    J Biochem Mol Toxicol; 2006; 20(4):174-82. PubMed ID: 16906522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease.
    Babu GN; Kumar A; Chandra R; Puri SK; Singh RL; Kalita J; Misra UK
    Neurochem Int; 2008 May; 52(6):1284-9. PubMed ID: 18308427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
    Putheti P; Soderstrom M; Link H; Huang YM
    J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
    Flechter S; Vardi J; Pollak L; Rabey JM
    J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glatiramer acetate induced hepatotoxicity.
    Subramaniam K; Pavli P; Llewellyn H; Chitturi S
    Curr Drug Saf; 2012 Apr; 7(2):186-8. PubMed ID: 22873505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.
    Fraser C; Hadjimichael O; Vollmer T
    J Neurosci Nurs; 2003 Jun; 35(3):163-70. PubMed ID: 12830664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.